STOCK TITAN
  1. Home
  2. News
  3. EMMA

Emmaus Life Sciences Incorporation - EMMA STOCK NEWS

Welcome to our dedicated news page for Emmaus Life Sciences Incorporation (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on Emmaus Life Sciences Incorporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Emmaus Life Sciences Incorporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Emmaus Life Sciences Incorporation's position in the market.

News
Emmaus Life Sciences Reports Delayed Filing of Annual Report
Rhea-AI Summary
Emmaus Life Sciences, a biopharmaceutical company specializing in sickle cell disease treatment, announced a delay in filing its Annual Report for 2023 due to ongoing accounting review. The company aims to submit the Form 10-K within the next week.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.38%
Tags
none
-
News
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
Rhea-AI Summary
Emmaus Life Sciences, Inc. (EMMA) has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder), marking a significant milestone in their mission to improve the lives of people with sickle cell disease (SCD) in Puerto Rico. Endari® is the first FDA-approved oral glutamine therapy for the reduction of acute complications of SCD in adult and pediatric patients five years and older. Clinical studies have shown that Endari® can significantly reduce the frequency of pain crises, hospitalizations, and other acute complications of SCD. The approval provides access to Endari® for patients living with SCD in Puerto Rico, adding to its existing approvals in the United States, Israel, United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman. Emmaus is committed to working with healthcare providers and payers in Puerto Rico to ensure accessibility of Endari® to all eligible patients, as well as raising awareness of SCD and the benefits of Endari® through educational programs for healthcare providers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.64%
Tags
none
-
News
Emmaus Life Sciences Reports Q3 2023 Financial Results
Rhea-AI Summary
Emmaus Life Sciences, Inc. (OTCQX: EMMA) reported on its financial condition and results of operations for the three and nine months ended September 30, 2023. Despite lower net revenues in the third quarter due to a shortage of finished inventory of Endari, the company generated modest net income by curtailing spending on activities unrelated to Endari sales. Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for the same periods in 2022. The company reported a net loss of $4.9 million for the nine months ended September 30, 2023, compared to a net loss of $10.8 million for the nine months ended September 30, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Emmaus Life Sciences Reports Management Changes
Rhea-AI Summary
Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Pursue New Projects
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
management
-
News
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none
-
News
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.75%
Tags
none
News
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Emmaus Life Sciences Provides Interim Shipment Data
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
News
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Dr. Niihara Meets with Local Indian Governor
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.7%
Tags
none
Stock EMMA logo
Emmaus Life Sciences Incorporation

OTC:EMMA

EMMA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

EMMA Stock Data

5.63M
29.02M
51.77%
0.08%
0.09%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States
Torrance

About EMMA

emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.